Men who have developed erectile dysfunction (ED) following surgery for prostate cancer usually do not have insurance coverage for ED treatment even though their insurance policies cover surgery for prostate cancer, according to an analysis presented today at the 103rd Annual Scientific Meeting of the American Urological Association.

Losing weight may help resolve erectile dysfunction in obese men, according to research presented today at the 103rd Annual Scientific Meeting of the American Urological Association (AUA).

Maxi-K gene therapy may be a safe and effective future option for men whose erectile dysfunction (ED) is not treatable with oral therapy. Two studies presented today at the 103rd Annual Scientific Meeting of the American Urological Association (AUA) may give hope to these individuals. Researchers presented their findings to reporters in a special press conference on May 20, 2008 at 10 a.m.

Active surveillance remains a viable option for low-risk, localized prostate cancer, according to two studies presented today during the Annual Scientific Meeting of the American Urological Association (AUA), yet researchers point out a strong need for regular monitoring and development of stronger clinical predictors of progression. Researchers presented their findings to the media on May 18, 2008 at 11:00 a.m.

Women and men tend to have different types of stress-related psychological disorders. Women have greater rates of depression and some types of anxiety disorders than men, while men have greater rates of alcohol-use disorders than women. A new study of emotional and alcohol-craving responses to stress has found that when men become upset, they are more likely than women to want alcohol.

FDA says "wait" to dying men.

Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene – p53 – is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

Men whose prostate cancer screenings show high grade prostatic intraepithelial neoplasia (HG-PIN) may find themselves in limbo, “stuck” between diagnoses – they are told prostate cancer has not yet developed, but it might, and they are advised to undergo repeated needle biopsies as a precaution.

Benign prostate enlargement affects most of the elder men and often compresses the urethra resulting in voiding symptoms. Dutch researcher Tim Idzenga has found a way to measure the resistance of the urethra using sound: via a microphone placed behind the scrotum. The sound spectrum of the recorded sound depends on how much the urethra has been compressed. The company IQ+ Medical BV will develop this system commercially.

The expected number of deaths from prostate cancer more than halved in the Tyrol after a programme was introduced to improve early detection and treatment of the disease, according to research published in April issue of the urology journal BJU International.

A new study by researchers at the University of Southern California (USC) has found evidence that supports gender-related differences in the development and survival of metastatic colon cancer.

Researchers at Rutgers’ Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.